In vitro activity of sulbactam/durlobactam against global isolates of carbapenem-resistant Acinetobacter baumannii.

The Journal of Antimicrobial Chemotherapy
Harald SeifertMichael Kresken

Abstract

To evaluate the activity of the novel broad-spectrum serine β-lactamase inhibitor durlobactam (ETX2514) combined with sulbactam against global isolates of carbapenem-resistant Acinetobacter baumannii with defined carbapenem resistance mechanisms compared with reference antimicrobials with known activity against Acinetobacter spp. The susceptibility of 246 carbapenem-resistant non-duplicate A. baumannii isolates to sulbactam/durlobactam, amikacin, colistin, imipenem/sulbactam/durlobactam, imipenem, meropenem, minocycline and sulbactam was tested using broth microdilution. Isolates were obtained from various body sites from patients in 37 countries and from six world regions between 2012 and 2016. Identification of carbapenem resistance mechanisms and assignment to A. baumannii clonal lineages was based on WGS. Sulbactam/durlobactam showed excellent activity comparable to colistin but superior to amikacin, minocycline and sulbactam. The sulbactam/durlobactam MIC50/90 values were 1/4 and 2/4 mg/L and the colistin MIC50/90 values were 0.5 and 1 mg/L, respectively. Comparatively, amikacin, minocycline and sulbactam MIC50/90 values were 256/≥512, 2/16 and 16/64 mg/L, respectively. Sulbactam/durlobactam had excellent in vitro potency ...Continue Reading

References

May 1, 1997·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·M E Jiménez-MejíasM Revuelta
May 17, 2002·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·G Christopher WoodBradley A Boucher
Mar 28, 2006·International Journal of Antimicrobial Agents·Neil WoodfordDavid M Livermore
Aug 3, 2006·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·L Poirel, P Nordmann
Jul 16, 2008·Clinical Microbiology Reviews·Anton Y PelegDavid L Paterson
Dec 10, 2009·The Journal of Antimicrobial Chemotherapy·Paul G HigginsHarald Seifert
Jan 7, 2015·Antimicrobial Agents and Chemotherapy·William F PenwellAlita A Miller
Apr 1, 2015·Clinical Infectious Diseases : an Official Publication of the Infectious Diseases Society of America·Crystal L JonesEmil Lesho
Oct 7, 2015·Intensive Care Medicine·José Garnacho-MonteroUNKNOWN European Society of Intensive Care Medicine
Apr 22, 2017·International Journal of Antimicrobial Agents·Spyros PournarasUNKNOWN Greek Study Group on Acinetobacter Antimicrobial Resistance
Jul 15, 2017·International Journal of Antimicrobial Agents·Harald SeifertPaul G Higgins
Dec 26, 2017·The Lancet Infectious Diseases·Evelina TacconelliUNKNOWN WHO Pathogens Priority List Working Group
Mar 7, 2019·Nature Reviews. Microbiology·Karen Bush, Patricia A Bradford
Mar 28, 2019·Clinical Microbiology and Infection : the Official Publication of the European Society of Clinical Microbiology and Infectious Diseases·E-T PiperakiG L Daikos
Nov 2, 2019·International Journal of Antimicrobial Agents·Harald SeifertPaul G Higgins
Nov 30, 2019·Critical Care : the Official Journal of the Critical Care Forum·José M CisnerosUNKNOWN Magic Bullet Working Group WP1

❮ Previous
Next ❯

Citations

Dec 4, 2020·Expert Review of Anti-infective Therapy·Marios KarvouniarisGaryphallia Poulakou
Dec 10, 2020·International Journal of Molecular Sciences·Juan C Vázquez-UchaAlejandro Beceiro
Apr 15, 2021·Expert Review of Clinical Pharmacology·Anselm Jorda, Markus Zeitlinger
Aug 24, 2021·Antimicrobial Agents and Chemotherapy·Jessica Howard-Anderson, David van Duin

❮ Previous
Next ❯

Related Concepts

Related Feeds

Beta-lactamase Inhibitors

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Beta-lactamase Inhibitors (ASM)

Beta-lactamase inhibitors are a class of antibiotics that inhibit beta-lactamases, a family of enzymes involved in bacterial resistance to beta-lactam antibiotics. Here is the latest research.

Carbapenems (ASM)

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Carbapenems

Carbapenems are members of the beta lactam class of antibiotics and are used for the treatment of severe or high-risk bacterial infections. Discover the latest research on carbapenems here.

Acinetobacter Infections

Acinetobacter infections have become common in hospitalized patients, especially in the intensive care unit setting and are difficult to treat due to their propensity to develop antimicrobial drug resistance. Discover the latest research on Acinetobacter Infections here.